These results emphasize the potential of [225Ac]Ac-PSMA as an effective therapy for advanced prostate cancer, especially regarding long-term tolerability, and may help guide future therapeutic decisions, optimize treatment protocols, and promote the further use of alpha-emitting therapies in oncology. The gene discussed is FOLH1; the disease is prostate cancer.